CClinicalTrials.gg
Status unknownNCT00389272Updated Oct 31, 2007

Adding a Second Drug for Febrile Children Treated With Acetaminophen

An interventional study of Ibuprofen, acetaminophen in Fever, sponsored by Assaf-Harofeh Medical Center. Status unknown at 1 site in Israel. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2007-10-31.

Sponsored by Assaf-Harofeh Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2006), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Months to 4 Years
Sex
All
01

Study summary

Fever is one of the most common symptoms in pediatrics and one of the most common reasons for visits in pediatricians' office and pediatric emergency departments. Many parents consider fever to be the most terrifying symptom.

Acetaminophen and ibuprofen are both effective and safe treatments for febrile children. In order to achieve better temperature control and to avoid toxicity it has been suggested to treat febrile children with alternating doses of acetaminophen and ibuprofen. Surveys in the USA and Spain found that this practice is very common. However, The safety and efficacy of such practice was never described.

Hypothesis:

Children who are still febrile after being treated with acetaminophen or ibuprofen will have greater temperature decrement if treated with another drug (acetaminophen for those treated with ibuprofen and ibuprofen for those treated with acetaminophen) than if treated with placebo.

Read the detailed description

Methods:

Design: randomized double blind placebo controlled study. Setting: The ED and pediatric ward of a large University affiliated Hospital

Participants:

Inclusion criteria:

  • Age: 6 mo- 4 years
  • Rectal temperature > 38.5
  • Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the ED.

Exclusion criteria:

  • Received more than 75 mg acetaminophen in the last 24 hours
  • Unable to take oral medications
  • Hypersensitivity to acetaminophen or ibuprofen
  • Varicella
  • Renal failure
  • Liver disease
  • Rectal temperature can't be measured (due to anatomical or medical problem)
  • Received both Ibuprofen and acetaminophen in the last 6 hours
  • Informed consent could not be granted

Intervention:

Patients will be recruited in the ED and pediatric ward at Assaf Harofeh Medical Center. Legal guardians of eligible patients will be approached for consent. After obtaining informed consent a detailed history regarding the way fever was managed during the current illness will be collected (appendix 1). Patients will be randomized in a ratio of 2:1 (by a computer generated list of random numbers) into one of two groups. Group A will be treated with oral suspension of ibuprofen 10mg/kg (if the patient received acetaminophen at home) or oral suspension of acetaminophen 15 mg/kg (if treated previously with ibuprofen). The second group will be treated with the same amount of oral placebo suspension. The parents and the physician will be blinded to the treatment given. Body departure will be recoded at base line and at 15, 30, 60, 90, 120, 180 minutes after the drug administration. Blood sample for serum concentrations of acetaminophen or/and ibuprofen will be taken at the time of routine blood sampling according to the attending physician decision. Serum concentrations will not be measured if the attending physician decides that blood tests are not indicated.

Primary outcome:

  • Maximal change in temperature during the 3-hour period after enrollment.

Secondary endpoints:

  • Proportion of patients with a drop of at least 1°C and 2°C in mean temperature at the end of the study (3 hours).
  • Decrement in fever at each time point, and the area under the temperature (versus time) curve for each group, calculated using the trapezoidal method. Continuous outcomes
  • Proportion of patients with temperature \< 38 at the end of the study (3 hours).
02

Conditions studied

  • Fever
03

In context

Lead sponsor

Assaf-Harofeh Medical Center is the lead sponsor of 258 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age: 6 mo- 4 years
  • Rectal temperature > 38.5
  • Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the

Exclusion criteria

Exclusion Criteria:

  • Received more than 75 mg acetaminophen in the last 24 hours
  • Unable to take oral medications
  • Hypersensitivity to acetaminophen or ibuprofen
  • Varicella
  • Renal failure
  • Liver disease
  • Rectal temperature can't be measured (due to anatomical or medical problem)
  • Received both Ibuprofen and acetaminophen in the last 6 hours
  • Informed consent could not be granted
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Interventions

  • DrugIbuprofen, acetaminophen
06

Study locations

1 of 1 sites recruiting
  • Pediatric Emergency Medicine Service, Assaf Harofeh Medical Center
    Zerifin, 70300, Israel
    • Eran Kozer, MD · Principal investigator
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00389272
Lead sponsor
Assaf-Harofeh Medical Center
First posted
Oct 18, 2006
Start date
Sep 2005
Completion
Dec 2008 (estimated)
Last update
Oct 31, 2007

Study contacts

Eran Kozer, MD
Contact
erank@asaf.health.gov.il
972 8 9779916
Eran Kozer
principal investigator · Assaf-Harofeh Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion